GMAB — Genmab A/S

Genmab Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total revenue grew by 21% year-over-year, driven by a 26% increase in recurring revenue.
• Operating profit surged by 52%, totaling $932 million for the first nine months of 2025.
• EPKINLY and TIVDAK sales increased by 54% year-over-year, contributing 25% to overall revenue growth.
• Cash reserves stood at approximately $3.4 billion, providing a solid financial foundation for future investments.
• Guidance for 2025 projects revenue between $3.5 billion and $3.7 billion, with expected operating profit of $1.1 billion to $1.4 billion.

2. Strategic Updates and Business Highlights:

• Genmab is focused on accelerating the development of its late-stage pipeline, including EPKINLY and Rina-S, with promising clinical data reported.
• The proposed acquisition of Merus is expected to enhance Genmab's portfolio, particularly with the addition of petosemtamab, which has received breakthrough therapy designations.
• EPKINLY is anticipated to receive approval for second-line follicular lymphoma soon, with significant growth potential expected in earlier lines of therapy.
• TIVDAK has launched in Germany, marking Genmab's first independent European market entry, with early uptake showing promise.

3. Forward Guidance and Outlook:

• The company remains on track for double-digit revenue and profit growth in 2025.
• Anticipated launch of Rina-S in 2027, with ongoing Phase III trials reinforcing confidence in its potential.
• Continued focus on disciplined capital allocation and strategic investments to support pipeline advancements and commercial execution.

4. Bad News, Challenges, or Points of Concern:

• Genmab decided to terminate the development of GEN1042 in first-line head and neck cancer due to insufficient data, which raises questions about the future of this asset in other indications.
• There was a noted miss in EPKINLY's performance this quarter, raising concerns about its near-term growth trajectory, particularly in the community setting.
• Competitive pressures exist in the oncology landscape, especially with emerging therapies in similar indications, necessitating strong differentiation for EPKINLY and Rina-S.

5. Notable Q&A Insights:

• Management expressed confidence in the competitive positioning of both petosemtamab and Rina-S, citing their potential as best-in-class therapies.
• EPKINLY's dual indication is seen as a strategic advantage, with expectations for rapid uptake in second-line follicular lymphoma.
• The company remains optimistic about the upcoming PDUFA for EPKINLY, with no current indications of issues that would prevent approval.
• There are ongoing discussions about the need for subcutaneous formulations to enhance competitiveness against other therapies in the market.

Overall, Genmab's Q3 2025 results reflect strong financial performance and strategic advancements, though challenges in competitive positioning and clinical development decisions warrant close attention.